1
One patient experienced an apparent hypersensitivity reaction that responded to conventional medications.
2
One patient had a hypersensitivity reaction, which was easily controlled using routine measures.
3
Only one patient developed a major hypersensitivity reaction to paclitaxel.
4
One patient with a hypersensitivity reaction also had persistent antibodies.
5
Conclusions: These results demonstrate that SBL could modulate the mast cell-mediated hypersensitivity reaction in allergy.
6
As a consequence, these mice did not mount a delayed-type hypersensitivity reaction after OVA challenge.
7
Three of 30 patients developed a hypersensitivity reaction.
8
We compared the incidence of hypersensitivity reaction associated with IV versus IM administration of pegylated ASNase.
9
Similarly, the skin delayed hypersensitivity reaction to Strep.
10
Results: No patient experienced a hypersensitivity reaction.
11
Adverse events, including those indicative of a possible hypersensitivity reaction, were collected for 42 days after each dose.
12
A severe hypersensitivity reaction occurred in 1 patient early during the first cycle, resulting in discontinuation of treatment.
13
In addition, UV light causes keratinocytes to release immunosuppressive factors which block contact hypersensitivity reaction and IL 1 activity.
14
Among the negative patients, 17.2% were treated with abacavir without any hypersensitivity reaction.
15
Two patients were not evaluable because they withdrew from the study because of a hypersensitivity reaction after the second cycle.
16
Our data indicate that epidermal cells modified during a delayed-type hypersensitivity reaction in vivo may suppress an antigen-specific T-cell proliferation.